EQT X, through its indirectly owned subsidiary Oak BidCo S.à r.l., has secured an ownership of 72.5% of the votes in OEM International Aktiebolag (publ) and has announced a public cash offer to all shareholders. The shares of OEM International are admitted to trading on Nasdaq Stockholm, Mid Cap. The total value of the offer is approximately SEK 15.2 billion.

OEM International is one of Europe's leading technology trading companies with 34 operating units in 15 countries. The group operates in the trade of components and systems from leading suppliers in selected markets in Europe. A well-structured local market organisation and efficient logistics make OEM a better alternative to the supplier’s own sales organisations.

Vinge’s team mainly consists of Sofie Bjärtun, Erik Sjöman, Joel Magnusson, Maximilian Bengtsson and Lovisa Jonassen (Capital Markets and Public M&A), Christina Kokko and Eléonore Friberg (M&A), Sebastian Örndahl, Noelia Martinez, Julia Rydin and Martin Hammarskiöld (Regulatory), Josefine Lanker (Banking and Finance), Christoffer Nordin and Elis Allmark (Commercial Agreements), Niclas Winnberg (Real Estate), Ebba Svenburg (Employment), Arvid Axelryd (Intellectual Property), Eva Fredriksson (IT), Hayaat Ibrahim (Compliance), Nicklas Thorgerzon (GDPR) and Julia Ulander Kull (Transaction Support Coordinator).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025